INSR and mucopolysaccharidosis type 1: Macromolecules conjugated to a peptidomimetic monoclonal antibody targeting the human insulin receptor (HIRMAb) have shown promise, with valanafusp alpha being developed for Mucopolysaccharidosis Type I (MPSI) [129,130,131].